Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human (165) Apply Human filter Veterinary (3) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Withdrawn applications Remove Withdrawn applications filter Paediatric investigation plans Remove Paediatric investigation plans filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Summaries of opinion (5) Apply Summaries of opinion filter Orphan designations (23) Apply Orphan designations filter Referrals (1) Apply Referrals filter

Product number

Authorisation status

Authorised (112) Apply Authorised filter Refused (2) Apply Refused filter Withdrawn (28) Apply Withdrawn filter

ATC code

Species

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

Withdrawal type

Initial authorisation (5) Apply Initial authorisation filter Post-authorisation (1) Apply Post-authorisation filter

Withdrawal date

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (2) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (12) Apply PM: decision on the application for modification of an agreed PIP filter RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) (1) Apply RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (5) Apply Yes filter

Compliance procedure number

Medicine type

Biosimilar Remove Biosimilar filter Exceptional circumstances Remove Exceptional circumstances filter Accelerated assessment (92) Apply Accelerated assessment filter Additional monitoring (613) Apply Additional monitoring filter Conditional approval (93) Apply Conditional approval filter Generic (350) Apply Generic filter Orphan medicine (320) Apply Orphan medicine filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

168 results

Remove all filtersRemove all filters

Medicine type Exceptional circumstances Remove Exceptional circumstances filter Biosimilar Remove Biosimilar filter

Medicine Direct healthcare professional communication Remove Direct healthcare professional communication filter Paediatric investigation plans Remove Paediatric investigation plans filter European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Withdrawn applications Remove Withdrawn applications filter

Sort by

List item

Human medicine European public assessment report (EPAR): Abasaglar (previously Abasria)

insulin glargine, Diabetes Mellitus
Date of authorisation: 09/09/2014, , Revision: 12, Authorised, Last updated: 24/09/2021
List item

Human medicine European public assessment report (EPAR): Abevmy

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 21/04/2021, , , Revision: 5, Authorised, Last updated: 15/12/2022
List item

Human medicine European public assessment report (EPAR): Abseamed

epoetin alfa, Anemia; Kidney Failure, Chronic; Cancer
Date of authorisation: 27/08/2007,
Date of refusal: 18/06/2009, , Revision: 22, Authorised, Last updated: 21/08/2023
List item

Human medicine European public assessment report (EPAR): Accofil

filgrastim, Neutropenia
Date of authorisation: 17/09/2014, , Revision: 14, Authorised, Last updated: 24/07/2023
List item

Human medicine European public assessment report (EPAR): Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals)

split influenza virus, inactivated, containing antigen: A/VietNam/1194/2004 (H5N1) like strain used (NIBRG-14), Influenza, Human; Immunization; Disease Outbreaks
Date of authorisation: 10/10/2009, , Revision: 11, Authorised, Last updated: 08/06/2022
List item

Human medicine European public assessment report (EPAR): Alpheon

recombinant human interferon alfa-2a, Hepatitis C, Chronic
Date of refusal: 05/09/2006, , Refused, Last updated: 28/06/2006
List item

Human medicine European public assessment report (EPAR): Alymsys

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 26/03/2021, , , Revision: 6, Authorised, Last updated: 26/07/2023
List item

Human medicine European public assessment report (EPAR): Amgevita

adalimumab, Arthritis, Psoriatic; Colitis, Ulcerative; Arthritis, Juvenile Rheumatoid; Spondylitis, Ankylosing; Psoriasis; Crohn Disease; Arthritis, Rheumatoid
Date of authorisation: 21/03/2017, , Revision: 11, Authorised, Last updated: 18/01/2023
List item

Human medicine European public assessment report (EPAR): Amsparity

adalimumab, Arthritis, Rheumatoid; Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing; Uveitis; Hidradenitis Suppurativa; Colitis, Ulcerative; Crohn Disease; Arthritis, Juvenile Rheumatoid
Date of authorisation: 13/02/2020, , , Revision: 4, Authorised, Last updated: 29/10/2021
List item

Human medicine European public assessment report (EPAR): Atriance

nelarabine, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 22/08/2007, , , Revision: 26, Authorised, Last updated: 16/01/2023
List item

Human medicine European public assessment report (EPAR): ATryn

Antithrombin alfa, Antithrombin III Deficiency
Date of authorisation: 28/07/2006, , , Revision: 16, Withdrawn, Last updated: 02/07/2019
List item

Human medicine European public assessment report (EPAR): Aybintio

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 19/08/2020, , , Revision: 7, Authorised, Last updated: 11/04/2023
List item

Human medicine European public assessment report (EPAR): Bekemv

Eculizumab, Hemoglobinuria, Paroxysmal
Date of authorisation: 19/04/2023, , Revision: 1, Authorised, Last updated: 06/07/2023
List item

Human medicine European public assessment report (EPAR): Bemfola

follitropin alfa, Anovulation
Date of authorisation: 26/03/2014, , Revision: 10, Authorised, Last updated: 19/12/2022
List item

Human medicine European public assessment report (EPAR): Benepali (updated)

etanercept, Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis
Date of authorisation: 13/01/2016, , Revision: 21, Authorised, Last updated: 14/09/2023
List item

Human medicine European public assessment report (EPAR): Binocrit

epoetin alfa, Anemia; Kidney Failure, Chronic
Date of authorisation: 28/08/2007, , Revision: 21, Authorised, Last updated: 21/08/2023
List item

Human medicine European public assessment report (EPAR): Biograstim

filgrastim, Neutropenia; Hematopoietic Stem Cell Transplantation; Cancer
Date of authorisation: 15/09/2008, , Revision: 8, Withdrawn, Last updated: 19/01/2017
List item

Human medicine European public assessment report (EPAR): Blitzima

rituximab, Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 13/07/2017, , Revision: 18, Authorised, Last updated: 02/02/2023
List item

Human medicine European public assessment report (EPAR): Brineura

cerliponase alfa, Neuronal Ceroid-Lipofuscinoses
Date of authorisation: 30/05/2017, , , , , Revision: 6, Authorised, Last updated: 16/08/2022
List item

Human medicine European public assessment report (EPAR): Bylvay

Odevixibat, Cholestasis, Intrahepatic
Date of authorisation: 16/07/2021, , , , Revision: 3, Authorised, Last updated: 05/07/2023
List item

Human medicine European public assessment report (EPAR): Byooviz

ranibizumab, Wet Macular Degeneration; Macular Edema; Diabetic Retinopathy; Myopia, Degenerative
Date of authorisation: 18/08/2021, , , Revision: 6, Authorised, Last updated: 14/04/2023
List item

Human medicine European public assessment report (EPAR): Cegfila (previously Pegfilgrastim Mundipharma)

pegfilgrastim, Neutropenia
Date of authorisation: 19/12/2019, , , Revision: 7, Authorised, Last updated: 24/02/2023
List item

Human medicine European public assessment report (EPAR): Ceplene

Histamine dihydrochloride, Leukemia, Myeloid, Acute
Date of authorisation: 07/10/2008, , , Revision: 12, Authorised, Last updated: 19/04/2023
List item

Human medicine European public assessment report (EPAR): Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau) (updated)

Chenodeoxycholic acid, Xanthomatosis, Cerebrotendinous; Metabolism, Inborn Errors
Date of authorisation: 10/04/2017, , , , Revision: 6, Authorised, Last updated: 18/09/2023
List item

Human medicine European public assessment report (EPAR): Cyltezo

adalimumab, Hidradenitis Suppurativa; Arthritis, Psoriatic; Psoriasis; Crohn Disease; Arthritis, Juvenile Rheumatoid; Uveitis; Arthritis, Rheumatoid; Colitis, Ulcerative; Spondylitis, Ankylosing
Date of authorisation: 10/11/2017, , , Revision: 2, Withdrawn, Last updated: 06/03/2019

Load more

168 results

Human medicine European public assessment report (EPAR): Abasaglar (previously Abasria)

Human medicine European public assessment report (EPAR): Abevmy

Human medicine European public assessment report (EPAR): Abseamed

Human medicine European public assessment report (EPAR): Accofil

Human medicine European public assessment report (EPAR): Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals)

Human medicine European public assessment report (EPAR): Alpheon

Human medicine European public assessment report (EPAR): Alymsys

Human medicine European public assessment report (EPAR): Amgevita

Human medicine European public assessment report (EPAR): Amsparity

Human medicine European public assessment report (EPAR): Atriance

Human medicine European public assessment report (EPAR): ATryn

Human medicine European public assessment report (EPAR): Aybintio

Human medicine European public assessment report (EPAR): Bekemv

Human medicine European public assessment report (EPAR): Bemfola

Human medicine European public assessment report (EPAR): Benepali (updated)

Human medicine European public assessment report (EPAR): Binocrit

Human medicine European public assessment report (EPAR): Biograstim

Human medicine European public assessment report (EPAR): Blitzima

Human medicine European public assessment report (EPAR): Brineura

Human medicine European public assessment report (EPAR): Bylvay

Human medicine European public assessment report (EPAR): Byooviz

Human medicine European public assessment report (EPAR): Cegfila (previously Pegfilgrastim Mundipharma)

Human medicine European public assessment report (EPAR): Ceplene

Human medicine European public assessment report (EPAR): Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau) (updated)

Human medicine European public assessment report (EPAR): Cyltezo